当前位置: 首页 > 期刊 > 《中国民康医学(上半月)》 > 2006年第6期
编号:11007706
万拉法新与阿普唑仑治疗广泛性焦虑症对照研究
http://www.100md.com 《中国民康医学》 2006年第6期
广泛性焦虑症,,广泛性焦虑症;万拉法新;阿普唑仑,1对象和方法,2结果,3讨论,参考文献
     【摘要】 目的:验证万拉法新治疗广泛性焦虑的疗效及不良反应。方法: 68例广泛性焦虑症按就医顺序分为两组,分别用万拉法新及阿普唑仑进行治疗,疗程6周,于治疗前及治疗后第1、2、4、6周末进行汉密顿焦虑量表(HAMA)、焦虑自评量表(SAS)、副反应量表(TESS)评定疗效及不良反应。 结果:万拉法新和阿普唑仑两药疗效相仿,万拉法新不良反应少而轻微。结论:万拉法新是治疗广泛性焦虑症较为理想的药物。

    【关键词 】 广泛性焦虑症;万拉法新;阿普唑仑

    A clinical control study of venlafaxine and alprazolam in the treatment of general anxiety disorder

    YU Hong-wei

    (Taian Mental Hospital of Demobilized Soldiers, Shandong 271000 , China)

    【Abstract】 Objective:To verify the clinical efficacy and the side effects of venlafaxine in the treatment of general anxiety disorder. Methods:68 patients were assigned to velafaxine group and alprazolam group respectively for 6 weeks. The efficacy and side effects were evaluated by HAMA, SAS and TESS before and after 1,2,3,4 and 6 weeks.Results: The efficacy of venlafaxine and alprazolam had no significant difference, but venlafaxine had fewer side effects.Conclusions: Venlafaxine is an effective and safe medicine in the treatment of general anxiety disorder.

    【Key words】Venlafaxine; Alprazolam; General anxiety disorder

    万拉法新是一种新型的抗抑郁药 ......

您现在查看是摘要页,全文长 4767 字符